Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies

被引:38
作者
Horowitz, Mark Abie [1 ,2 ]
Taylor, David [3 ,4 ]
机构
[1] Univ Coll London UCL, Div Psychiat, London, England
[2] North East London NHS Fdn Trust NELFT, Res & Dev Dept, London, England
[3] Maudsley Hosp & Inst Psychiat, Pharm & Pathol, London, England
[4] Kings Coll London, Psychopharmacol, London, England
关键词
Withdrawal; discontinuation; SSRI; SNRI; confounding; DOUBLE-BLIND; SYMPTOMS; PREVENTION; PAROXETINE; DEPRESSION; DRUG; METAANALYSIS; ESCITALOPRAM; AGOMELATINE; EFFICACY;
D O I
10.1192/bja.2021.62
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
We now recognise that withdrawal symptoms from antidepressants are common, and can be severe and long-lasting in some people. Many withdrawal symptoms overlap with symptoms of anxiety or depression, making it difficult to distinguish withdrawal from relapse. We describe how their onset soon after dose reduction, the association of psychological with physical symptoms, their prompt response to reinstatement, and their typical 'wave' pattern of onset, peak and resolution can help distinguish withdrawal symptoms from relapse. We also examine evidence that suggests that antidepressant withdrawal symptoms are misdiagnosed as relapse in discontinuation studies aimed at demonstrating the ability of antidepressants to prevent future relapse (relapse prevention properties). In these discontinuation studies people have their antidepressants stopped abruptly, or rapidly, making withdrawal symptoms very likely, and little effort is made to measure withdrawal symptoms or distinguish them from relapse. We conclude that there is currently no robust evidence for the relapse prevention properties of antidepressants, and current guidance might need to be re-evaluated.
引用
收藏
页码:297 / 311
页数:15
相关论文
共 62 条
[41]   Addiction and dependence in DSM-V [J].
O'Brien, Charles .
ADDICTION, 2011, 106 (05) :866-867
[42]   PAROXETINE IN THE TREATMENT OF PANIC DISORDER - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
OEHRBERG, S ;
CHRISTIANSEN, PE ;
BEHNKE, K ;
BORUP, AL ;
SEVERIN, B ;
SOEGAARD, J ;
CALBERG, H ;
JUDGE, R ;
OHRSTROM, JK ;
MANNICHE, PM .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 167 :374-379
[43]   Discontinuation syndromes with selective serotonin reuptake inhibitors - Are there clinically relevant differences? [J].
Olver, JS ;
Burrows, GD ;
Norman, TR .
CNS DRUGS, 1999, 12 (03) :171-177
[44]  
Papp A., 2018, PRIMARY CARE COMPANI, V20, p18m02311
[45]   Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects [J].
Read, John ;
Williams, James .
CURRENT DRUG SAFETY, 2018, 13 (03) :176-186
[46]   Withdrawal Confounding in Randomized Controlled Trials of Antipsychotic, Antidepressant, and Stimulant Drugs, 2000-2017 [J].
Recalt, Alexander M. ;
Cohen, David .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2019, 88 (02) :105-113
[47]   Drug Discontinuation Effects Are Part of the Pharmacology of a Drug [J].
Reidenberg, Marcus M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (02) :324-328
[48]   Post-SSRI sexual dysfunction [J].
Reisman, Yacov .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 368
[49]   Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial [J].
Rosenbaum, JF ;
Fava, M ;
Hoog, SL ;
Ascroft, RC ;
Krebs, WB .
BIOLOGICAL PSYCHIATRY, 1998, 44 (02) :77-87
[50]  
Royal College of Psychiatrists, 2019, Position Statement on Antidepressants and Depression